

**Supplementary information**

---

**A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling**

---

In the format provided by the authors and unedited

## Supplementary Notes

### **A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling**

Yoshiaki Abe<sup>1</sup>, Mamiko Sakata-Yanagimoto<sup>2,3,4\*</sup>, Manabu Fujisawa<sup>2</sup>, Hiroaki Miyoshi<sup>5</sup>, Yasuhito Suehara<sup>3</sup>, Keiichiro Hattori<sup>3</sup>, Manabu Kusakabe<sup>2,3</sup>, Tatsuhiro Sakamoto<sup>2,3</sup>, Hidekazu Nishikii<sup>2,3</sup>, Tran B. Nguyen<sup>2</sup>, Yohei Owada<sup>6</sup>, Tsuyoshi Enomoto<sup>6</sup>, Aya Sawa<sup>7</sup>, Hiroko Bando<sup>8</sup>, Chikashi Yoshida<sup>9</sup>, Rikako Tabata<sup>10</sup>, Toshiki Terao<sup>10</sup>, Masahiro Nakayama<sup>11</sup>, Koichi Ohshima<sup>5</sup>, Kensuke Usuki<sup>12</sup>, Tatsuya Oda<sup>6</sup>, Kosei Matsue<sup>10</sup>, and Shigeru Chiba<sup>2,3\*</sup>

<sup>1</sup> *Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba.*

<sup>2</sup> *Department of Hematology, Faculty of Medicine, University of Tsukuba.*

<sup>3</sup> *Department of Hematology, University of Tsukuba Hospital.*

<sup>4</sup> *Division of Advanced Hemato-Oncology, Transborder Medical Research Center, University of Tsukuba.*

<sup>5</sup> *Department of Pathology, School of Medicine, Kurume University.*

<sup>6</sup> *Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba.*

<sup>7</sup> *Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital.*

<sup>8</sup> *Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba.*

<sup>9</sup> *Department of Hematology, National Hospital Organization, Mito Medical Center.*

<sup>10</sup> *Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center.*

<sup>11</sup> *Department of Otolaryngology, Head and Neck Surgery, University of Tsukuba.*

<sup>12</sup> *Department of Hematology, NTT Medical Center Tokyo.*

\* *Correspondence*

1 **Related to “Human LN BECs: ten subclusters”**

2 The following is a comment regarding BEC subcluster-specific marker genes.

3 ABECs are characterized by selective expression of *GJA5* (Fig. 2h,i; Extended Data Fig. 2a),  
4 defined as a marker of larger arteries in murine tissues, including LNs<sup>1,2</sup>. By contrast, caBECs  
5 specifically express *SSUH2* (Fig. 2h,i; Extended Data Fig. 2a), a marker of arteries of varying size in  
6 different mouse tissues<sup>1</sup>. aBECs are characterized by expression of *INSR* (Fig. 2h; Extended Data  
7 Fig. 2a) and *EDNRB* (Fig. 2i), both capillary markers in mouse livers, lungs, and colon<sup>1</sup>. tBECs  
8 belong to a small but highly distinct subcluster that selectively expresses *PGF* and *LY6H* (Fig. 2h,i;  
9 Extended Data Fig. 2a). *PGF* is described as an endothelial tip cell marker in human lung cancer<sup>3</sup>,  
10 whereas *LY6H* has not been shown to be a specific marker in mice or humans<sup>1</sup>. Other human tip cell  
11 markers, including *CXCL4*, *PXDN*, and *LXN*<sup>3</sup>, were identified as DEGs in tBECs (Fig. 2h;  
12 Supplementary Table 5). cBECs are characterized by abundant *PLVAP* and *CA4* expression (Fig.  
13 2h,i; Extended Data Fig. 2a), in agreement with mouse data describing them both as capillary  
14 markers in multiple tissues<sup>1</sup>. C-aHEVs express DEGs of cBECs (including *CA4*) and aHEVs (Fig.  
15 2h,i; Supplementary Table 5), indicative of the transitioning nature of C-aHEVs. Also, *HES1*, a  
16 capillary marker in several mouse tissues, was highly expressed in C-aHEVs (Fig. 2h)<sup>1</sup>. C-aHEVs  
17 and aHEVs express genes encoding heat shock proteins (*HSPA1A*, *HSP90AA1*, and *HSPA1B*), as  
18 well as those involved in NFκB (*NFKB1A* and *NFKB1Z*) and JNK (*JUN*, *JUNB*, *JUND*, *FOS*, and

19 *FOSB*) activation. They also express genes associated with oscillatory shear stress (*EGRI*, *ICAMI*,  
20 *MT2A*, *MT2X*, and *ADM*) at higher levels than do cBECs and hHEVs (Extended Data Fig. 2b;  
21 Supplementary Tables 5,6)<sup>4</sup>. aHEVs, hHEVs, and CXCL10-HEVs all express genes specific to  
22 HEVs, including *ACKR1*, *C7*, and *CH25H* (Supplementary Table 5)<sup>5</sup>. CXCL10-HEVs are unique in  
23 their expression of the chemokines *CXCL9*, *CXCL10*, and *CXCL11* (Fig. 2h,i). Some suggest that a  
24 subset of HEVs express *CXCL10*, which facilitates trafficking of activated T cells and monocytes  
25 across HEVs<sup>6,7</sup>, though others have not detected *CXCL10* mRNA in HEVs<sup>8</sup>. Therefore, the CXCL10  
26 function in HEVs remains unclear<sup>9</sup>. Mouse LNs have a BEC subpopulation with highly similar  
27 phenotypes to CXCL10-HEVs that exhibit a prominent interferon signalling signature, although they  
28 were classified as capillary BECs<sup>2</sup>. VBECs are characterized by high expression of *CPE* and  
29 *VCAMI* (Fig. 2h; Extended Data Fig. 2a; Supplementary Table 5), which are markers of large  
30 veins<sup>1,2</sup>.

31 We examined the expression of marker genes for mouse LN BEC subclusters<sup>2</sup> in our human  
32 BEC data and summarized an assumed correspondence relationship between mouse and human LN  
33 (Extended Data Fig. 2k,l).

34

### 35 **Related to “Human LN LECs: eight subclusters”**

36 The following discussion addresses results of unsupervised clustering in MFLN LECs, DEG

37 analysis across subclusters, trajectory analysis, and IF staining.

38 Putative cLECs (LEC I), particular SCS ceiling LECs that cover medullary regions (III),  
39 capillary LECs in surrounding tissues (IV), and valve LECs (V) were observed in our clustering, as  
40 suggested by Takeda et al and Xiang et al<sup>10,11</sup>, though we annotated LECs III and IV as collectLECs  
41 and msLECs, respectively (Fig. 3a). We observed several slight differences between our analysis and  
42 previous analyses<sup>10,11</sup>. First, our analysis detected a subcluster in which gene expression patterns  
43 matched those seen in bLECs, a cell type proposed by Xiang et al (e.g. intermediate *BMP2*  
44 expression between cLECs and fLECs) (Fig. 3c; Extended Data Fig. 3a)<sup>11</sup>, although bLECs were not  
45 detected by Takeda et al (Fig. 3e)<sup>10</sup>. Second, we initially could not identify fLECs and pfsLECs as  
46 distinct subclusters<sup>10,11</sup>. Lastly, two valve LEC subclusters (Up- and Down-valves) were identified as  
47 distinct, in contrast to a previous study that identified them after applying sub-clustering analysis to  
48 an initially-identified valve cluster (LEC V) (Fig. 3e)<sup>10</sup>. We speculate that these inconsistencies are  
49 due to the fact that previous studies collected LEC-enriched cells based on PDPN positivity in flow  
50 cytometric analysis, and thus LECs with relatively low PDPN expression may have been  
51 overlooked. Indeed, *PDPN* expression was particularly low in bLECs and down-valves (Extended  
52 Data Fig. 3a).

53 DEG analysis has revealed that the “fLEC and pfsLEC” subcluster is unique in harbouring  
54 more than twice as many DEGs as other LEC subclusters (Extended Data Fig. 3b). These DEGs

55 include chemokine genes such as *CXCL1*, *CXCL5*, and *CCL20*, and genes associated with immune  
56 cell adhesion, including *ICAMI*, *VCAMI*, and *SELE* (Extended Data Fig. 3a,c; Supplementary Table  
57 8), supporting the immunological function of fLECs in cell trafficking and migration. Genes  
58 reportedly specific to pfsLECs (e.g. *MARCO* and *CLEC4G*<sup>11</sup>) were also detected as top DEGs for the  
59 “fLEC and pfsLEC” subcluster (Extended Data Fig. 3a,c; Supplementary Table 8)<sup>10,11</sup>. *ACKR4*,  
60 *MFAP4*, *CCL21*, *CLDN11*, and *GJA4* were also consistently identified as top DEGs for cLECs,  
61 collectLECs, msLEC, valve LECs (both Up- and Down-valves), and down-valves, respectively (Fig.  
62 3c; Extended Data Fig. 3a,c)<sup>10</sup>.

63 To verify that a single “fLEC and pfsLEC” subcluster consists of both fLECs and pfsLECs,  
64 we applied unbiased sub-clustering analysis to the “fLEC and pfsLEC” subcluster. As expected, it  
65 comprised two transcriptionally distinct populations (Extended Data Fig. 3d). In agreement with the  
66 findings of Takeda et al, the proportion of pfsLECs was smaller than that of fLECs (Extended Data  
67 Fig. 3e)<sup>10</sup>. Notably, in DEG analysis between fLECs and pfsLECs, genes described as specific to  
68 LEC II and VI<sup>10</sup> were separately detected as top DEGs for fLECs and pfsLECs, respectively  
69 (Extended Data Fig. 3f; Supplementary Table 9).

70 Next, we performed trajectory analysis on integrated LEC data. We identified all LEC  
71 subclusters in a *Monocle 3*-generated cell object (Extended Data Fig. 3g). As expected, bLECs and  
72 collectLECs were adjacent to cLECs (Extended Data Fig. 3h). Remarkably, a trajectory from fLEC

73 and pfsLEC subclusters connected with remaining LEC subclusters in the middle region of bLECs  
74 and msLECs, and a direct trajectory connection was observed between pfsLECs and msLECs  
75 (Extended Data Fig. 3h), supporting positional relationships inferred across these subclusters<sup>11</sup>. Both  
76 Up- and Down-valves were connected to collectLECs (Extended Data Fig. 3h), supporting the  
77 annotation of collectLECs (Fig. 3d).

78 IF staining showed that PAI1- (encoded by *SERPINE1*) positive bLECs were exclusively  
79 embedded in the intermediate area of the SCS (Extended Data Fig. 3i). PTX3-positive LECs  
80 (msLECs) were preferentially located at the medulla (Extended Data Fig. 3j), although a small  
81 proportion of cLECs also showed PTX3 positivity (Fig. 3c; Extended Data Fig. 3j). MARCO-  
82 positive LECs (pfsLECs) were preferentially situated at perifollicular sinuses (Extended Data Fig.  
83 3k), as shown in mice<sup>11</sup>. MFAP4-positive LECs (collectLECs) were observed only in afferent and  
84 efferent collecting vessels (Extended Data Fig. 3l).

85

#### 86 **Related to “Human LN NESCs: twelve subclusters”**

87 The following discussion addresses results regarding the annotation of TRCs, PCs, MRCs, and  
88 FDCs.

89 DEG analysis showed that TRCs were marked by high *CCL19* and *CCL21* expression (Fig.  
90 4d,e; Supplementary Table 10)<sup>12</sup>, and PCs by specific expression of *NDUFA4L2* and *HIGD1B* (Fig.

91 4d,e; Supplementary Table 10)<sup>13</sup>. Approximately half of MRC DEGs were seen in FDC DEGs  
92 (Supplementary Table 10), consistent with the idea that MRCs differentiate into FDCs<sup>14</sup>. FDC  
93 markers *FDCSP*, *CR2*, and *FCER2* were correctly detected as FDC-specific DEGs (Fig. 4d,e;  
94 Supplementary Table 10).

95 GO analysis revealed that TRCs were enriched with GOs related to leukocyte and dendritic  
96 cell migration (Fig. 4i; Supplementary Table 12), in accordance with their reported function in  
97 recruiting naive T cells and dendritic cells to the T-cell zone to facilitate interaction<sup>12</sup>. Genes  
98 associated with smooth muscle structure or contraction were enriched in PCs and in SMC  
99 subclusters, whereas PCs abundantly expressed genes associated with blood vessel development  
100 (Fig. 4i; Supplementary Table 12). MRCs and FDCs were highly enriched with GOs relevant to  
101 cytokine- and chemokine-mediated signalling and antigen processing and presentation (Fig. 4i;  
102 Supplementary Table 12), consistent with their role in positioning and presenting antigens to B  
103 cells<sup>12</sup>. Finally, FDCs expressed genes involved in immunoglobulin-mediated immune response and  
104 B-cell-mediated immunity (Fig. 4i; Supplementary Table 12)<sup>12</sup>.

105 IF staining showed HIGD1B-positive cells (PCs) were observed around BECs, including  
106 arteries and HEVs (Extended Data Fig. 4n), and were more prevalent around HEVs in IFRs (aHEVs)  
107 than around hHEVs (Extended Data Fig. 4n), indicating that they may support lymphocyte  
108 recruitment and maintain endothelial cell integrity<sup>12</sup>. MRCs and FDCs were identified as BAFF- and



109 CR2 (also known as CD21)-positive, respectively (Extended Data Fig. 4o).

110 We examined the expression of key genes for mouse LN NESC subclusters<sup>15</sup> in our human  
111 NESC data and assumed a correspondence relationship between mouse and human LNs. Although  
112 some degree of correlation was detected between mouse and human LN NESTs, we observed more  
113 complicated heterogeneity in human LN NESTs than in mouse LNs and found that mouse NESC  
114 markers were not necessarily specific to human NESC counterparts (Extended Data Fig. 4q,r).

115

#### 116 **Additional basic information of the single-cell LNNHC atlas**

117 All subclusters identified in the single-cell LNNHC atlas included cells from all MFLN samples  
118 with some variations in cell proportion (Extended Data Fig. 5a). Notably, NHCs from a patient with  
119 a benign tumour (MFLN 8) were distributed uniformly among NHCs from all MFLN samples  
120 (Extended Data Fig. 5b). Furthermore, in NHC subclusters harbouring at least 50 cells from the  
121 sample MFLN 8, 80–100% of the top DEGs for all MFLN sample subclusters matched MFLN 8  
122 DEGs (Extended Data Fig. 5c).

123 We also profiled DEGs between mLN and pLN NHC subclusters using MFLN data  
124 (Supplementary Table 13). In this dataset, we observed markedly higher expression of *MADCAM1*  
125 in mLN HEV subclusters (aHEVs and hHEVs) compared with pLN counterparts (Extended Data  
126 Fig. 6a; Supplementary Table 13), in agreement with *MADCAM1*-dependent manners of

127 lymphocyte homing in mLN HEVs<sup>7</sup>. Consistently, GO analysis of DEGs between mLN and pLN  
128 subclusters showed that mLN HEV subclusters were enriched with *MADCAM1*-containing GO  
129 terms associated with cell adhesion and interactions with integrin (Extended Data Fig. 6b;  
130 Supplementary Table 14). We also found that multiple mLN NHC subclusters (particularly, NESC  
131 subclusters) highly expressed genes associated with inflammatory response including *PTX3*, *CCL2*,  
132 and *TNFAIP6* relative to pLN counterparts (Extended Data Fig. 6a,b; Supplementary Table 13).  
133 Consistent with the constant exposure of mLNs to enterobacteria-derived factors, GO terms  
134 associated with inflammatory response, TNF-signalling, and response to molecules of bacterial  
135 origin were enriched in mLN LEC and NESC subclusters (Extended Data Fig. 6b; Supplementary  
136 Table 14). Additionally, pLN LEC and NESC subclusters abundantly expressed genes associated  
137 with the maintenance of LN homeostasis and structures (Extended Data Fig. 6a,b; Supplementary  
138 Tables 13,14).

139

#### 140 **Additional prognostic analyses**

141 We tested the prognostic value of the markers proposed in our analyses (*LY6H*, *LOX*, *TDO2*, and  
142 *REMI*) in the intermediate prognosis group of FL. Notably, we found that elevated *LOX* and *TDO2*  
143 expressions were prognostic even in the intermediate prognosis group, while the prognostic

144 efficiency of *LY6H* expression was slightly not significant and that of *REMI* expression was not  
145 prognostic (Extended Data Fig. 9f).

146 Since these prognostic markers were derived primarily from TRCs or tBECs, we developed a  
147 FL TRC signature (Supplementary Table 19) and evaluated its prognostic proficiency. However, we  
148 could not extract sufficient number of genes for developing a FL tBEC signature. As a result, we  
149 observed no significant difference in the overall survival of patients with high and low FL TRC  
150 signature (data not shown).

151 The upregulation of tip cell markers (*LY6H* and *LOX*) was prognostic in FL (Fig. 7a,b),  
152 suggesting that enhanced tumour angiogenesis might affect FL prognosis, hence we also examined  
153 the prognostic impact of conventional pan-BEC markers, *PECAMI* and *CDH5*<sup>16</sup>. However, we did  
154 not detect any adverse prognostic impact of these markers in the microarray dataset<sup>17</sup> (Extended  
155 Data Fig. 9g).

156

#### 157 **Related to “Observation of NHC subclusters across lymphomas”**

158 The following addresses findings observed in scRNA-seq analysis of PTCL and tDLBCL stroma.

159 Unsupervised clustering analysis of integrated MFLN and lymphoma NHC data detected  
160 almost all NHC subclusters in both PTCL and tDLBCL (Extended Data Fig. 10a–d). Furthermore,  
161 we found that BECs and LECs in these lymphomas consistently increased and decreased,

162 respectively, as observed in FL (Extended Data Fig. 10b,d). tDLBCL BECs contained abundant  
163 arterial subclusters and CXCL10-HEVs (Extended Data Fig. 10d), suggesting accelerated  
164 angiogenesis and elevated HEV activities. Furthermore, we observed considerable alterations in the  
165 tDLBCL NESC proportions compared with the MFLN counterparts: the proportion of advSCs,  
166 medullary SCs, TNF-SCs, C7-SCs, AGT-SCs, and TRCs decreased considerably, whereas that of  
167 FSCs (MRCs and FDCs) increased drastically in tDLBCL, and the perivascular cell subcluster  
168 compositions remained relatively comparable (Extended Data Fig. 10d). Representative DEGs  
169 upregulated in FL subclusters, including *LY6H* and *LOX* at tBECs, *SELE* at HEV subclusters, and  
170 *VCAMI* at FSCs, were also observed in tDLBCL stroma, although some key DEGs were not  
171 validated, probably because of the small sample size of tDLBCL cohort (Extended Data Fig. 10e). In  
172 line with the findings of analyses on MFLN and FL NESCs (Fig. 4g,h, 5a), trajectories in tDLBCL  
173 NESCs indicated that non-FSC subclusters had differentiated into FSCs (Extended Data Fig. 10f–h),  
174 likely representing a terminal form of stromal remodelling in FL.

175 **Supplementary references**

- 176 1. Kalucka, J., *et al.* Single-Cell Transcriptome Atlas of Murine Endothelial Cells. *Cell* **180**,  
177 764-779.e720 (2020).
- 178 2. Brulois, K., *et al.* A molecular map of murine lymph node blood vascular endothelium at  
179 single cell resolution. *Nature communications* **11**, 3798 (2020).
- 180 3. Goveia, J., *et al.* An Integrated Gene Expression Landscape Profiling Approach to Identify  
181 Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. *Cancer cell* **37**, 21-  
182 36.e13 (2020).
- 183 4. Bondareva, O., *et al.* Identification of atheroprone shear stress responsive regulatory elements  
184 in endothelial cells. *Cardiovascular research* **115**, 1487-1499 (2019).
- 185 5. Lee, M., *et al.* Transcriptional programs of lymphoid tissue capillary and high endothelium  
186 reveal control mechanisms for lymphocyte homing. *Nature immunology* **15**, 982-995 (2014).
- 187 6. Nagakubo, D., *et al.* A high endothelial venule secretory protein, mac25/angiomodulin,  
188 interacts with multiple high endothelial venule-associated molecules including chemokines.  
189 *Journal of immunology (Baltimore, Md. : 1950)* **171**, 553-561 (2003).
- 190 7. von Andrian, U.H. & Mempel, T.R. Homing and cellular traffic in lymph nodes. *Nature*  
191 *reviews. Immunology* **3**, 867-878 (2003).
- 192 8. Janatpour, M.J., Hudak, S., Sathe, M., Sedgwick, J.D. & McEvoy, L.M. Tumor necrosis

- 193 factor-dependent segmental control of MIG expression by high endothelial venules in  
194 inflamed lymph nodes regulates monocyte recruitment. *The Journal of experimental medicine*  
195 **194**, 1375-1384 (2001).
- 196 9. Miyasaka, M. & Tanaka, T. Lymphocyte trafficking across high endothelial venules: dogmas  
197 and enigmas. *Nature reviews. Immunology* **4**, 360-370 (2004).
- 198 10. Takeda, A., *et al.* Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell  
199 Heterogeneity and Mechanisms of Homing for Neutrophils. *Immunity* **51**, 561-572.e565  
200 (2019).
- 201 11. Xiang, M., *et al.* A Single-Cell Transcriptional Roadmap of the Mouse and Human Lymph  
202 Node Lymphatic Vasculature. *Frontiers in cardiovascular medicine* **7**, 52 (2020).
- 203 12. Krishnamurty, A.T. & Turley, S.J. Lymph node stromal cells: cartographers of the immune  
204 system. *Nature immunology* **21**, 369-380 (2020).
- 205 13. Vanlandewijck, M., *et al.* A molecular atlas of cell types and zonation in the brain vasculature.  
206 *Nature* **554**, 475-480 (2018).
- 207 14. Fletcher, A.L., Acton, S.E. & Knoblich, K. Lymph node fibroblastic reticular cells in health  
208 and disease. *Nature reviews. Immunology* **15**, 350-361 (2015).
- 209 15. Rodda, L.B., *et al.* Single-Cell RNA Sequencing of Lymph Node Stromal Cells Reveals  
210 Niche-Associated Heterogeneity. *Immunity* **48**, 1014-1028.e1016 (2018).

- 211 16. Taskinen, M., *et al.* Prognostic impact of CD31-positive microvessel density in follicular  
212 lymphoma patients treated with immunochemotherapy. *European journal of cancer (Oxford,*  
213 *England : 1990)* **46**, 2506-2512 (2010).
- 214 17. Leich, E., *et al.* Follicular lymphomas with and without translocation t(14;18) differ in gene  
215 expression profiles and genetic alterations. *Blood* **114**, 826-834 (2009).